Skip to Content

Ipsen SA IPSEF

Morningstar Rating
$132.50 +14.90 (12.67%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

IPSEF is trading at a 199% premium.
Price
$132.58
Fair Value
$865.32
Uncertainty
High
1-Star Price
$126.45
5-Star Price
$417.97
Economic Moat
Pmkjn
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IPSEF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$117.60
Day Range
$132.50132.50
52-Week Range
$108.75132.50
Bid/Ask
$117.45 / $127.97
Market Cap
$11.00 Bil
Volume/Avg
2,856 / 1,446

Key Statistics

Price/Earnings (Normalized)
13.54
Price/Sales
3.09
Dividend Yield (Trailing)
0.98%
Dividend Yield (Forward)
0.98%
Total Yield
0.98%

Company Profile

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Core
Total Number of Employees
5,325

Competitors

Valuation

Metric
IPSEF
EXEL
UCB
Price/Earnings (Normalized)
13.5421.8329.43
Price/Book Value
2.593.012.89
Price/Sales
3.093.725.09
Price/Cash Flow
13.3120.0629.16
Price/Earnings
IPSEF
EXEL
UCB

Financial Strength

Metric
IPSEF
EXEL
UCB
Quick Ratio
0.863.230.84
Current Ratio
1.173.461.32
Interest Coverage
21.203.88
Quick Ratio
IPSEF
EXEL
UCB

Profitability

Metric
IPSEF
EXEL
UCB
Return on Assets (Normalized)
12.69%9.61%5.10%
Return on Equity (Normalized)
21.64%12.20%8.82%
Return on Invested Capital (Normalized)
19.82%8.59%7.41%
Return on Assets
IPSEF
EXEL
UCB
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
HxqbxkkwxVhpsb$77.8 Bil
Zoetis Inc Class A
ZTS
KnlbjbnsqMzhg$76.7 Bil
Haleon PLC ADR
HLN
DgysbxpRhjmj$38.2 Bil
Teva Pharmaceutical Industries Ltd ADR
TEVA
VdfbgvgbwRzqn$19.4 Bil
Viatris Inc
VTRS
SnzjhgjdStwk$12.2 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
SlrjbdgMrh$11.9 Bil
Catalent Inc
CTLT
ZfcdpvxbtHyxjhl$9.9 Bil
Perrigo Co PLC
PRGO
KqnmshbbMwm$3.5 Bil
Prestige Consumer Healthcare Inc
PBH
VltzxrwqBxtnmm$3.3 Bil
Curaleaf Holdings Inc
CURLF
MqbfvjmqXxwt$3.0 Bil

Sponsor Center